Report Description
The Global Genomic Biomarkers Market is estimated to expand at a substantial CAGR during the forecast period, 2021-2028. Genomic biomarkers are measurable Deoxyribonucleic acid (DNA) and Ribonucleic acid (RNA) characteristics, which act as indicators of diagnosis, normal biologic processes, pathogenic processes and therapy selection. These biomarkers reflect disease susceptibility, disease expression, and disease outcome or other intervention. Easily detection of variants in the DNA code, genomic biomarkers facilitate early discovery of diseases by predicting its possibility and enhances patient care by monitoring the outcomes.
Genomic Biomarkers Market Trends, Drivers, Restraints, and Opportunities:
- The increasing affliction of chronic diseases such as cardiovascular diseases, cancer, strokes, and arthritis is attributed to the growing genomic biomarkers market. As per the estimation by the World Health Organization in 2018, around 16% of deaths around the world are caused due to cancer trailed by cardiovascular diseases.
- Soaring demand for marginally invasive procedures and technological progressions are anticipated to increase in the demand for genomic biomarkers.
- Huge costs, complicated development process, strict government policies, and lack of uniform means to validate the products of manufacturers can restraint the growth of the genomic biomarkers market during the forecast period.
- Progressing R&D and the development of advanced infrastructure that allows data sharing along with the call for individualized medicines are expected to propel the further development of the market during the forecast period.
Scope of the Genomic Biomarkers Market Report:
The report on the global genomic biomarkers market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Base Year
|
2020
|
Historic Data
|
2018 & 2019
|
Forecast Period
|
2021–2028
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
|
Global Genomic Biomarkers Market Segment Insights:
Oncology Segment is Expected to Dominate the Market
On the basis of applications, the global genomic biomarkers market can be segmented into oncology, cardiovascular diseases, neurological diseases, renal disorders, and others. The oncology segment is estimated to dominate the market during the forecast period. The growth of the segment is owing to the predominance use of the devices for various applications related to types of cancers such as prostate, breast, and lung cancer. Moreover, push-in target therapies along with technological improvements and dependability on oncology biomarkers is estimated to drive the growth of the segment during the forecast period. Increasing unhealthy lifestyle and wide culture of smoking have prompted biopharmaceutical companies to prioritize the expansion of oncology products such as genomic biomarkers.
Diagnostic & Research Laboratories to occupy significant market share
In terms of end users, the global genomic biomarkers market can be divided into diagnostic & research laboratories, hospitals, and others. The diagnostic & research laboratories segment is anticipated to account for a significant market share due to increase in number of patients who adopt genomic biomarkers for various diagnostic and research purposes.
North America constitutes a large share of the global market
Based on regions, the global genomic biomarkers market can be classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounted for a prime share in terms of revenue and is anticipated to retain its position during the forecast period. Some of the key reasons pushing the market growth in the region can be attributed to advanced healthcare facilities, encouraging government policies, and vast research funds. Activities in extensive R&D activities, cutting-edge technologies, and significant funding by governments along with private players especially in the US is projected to exhibit of the regional market growth during the forecast period.
Segments
Segments Covered in the Report
The global genomic biomarkers market can be divided based on components, delivery modes, functions, end users and regions.
Applications
- Oncology
- Cardiovascular Diseases
- Neurological Diseases
- Renal Disorders
- Others
End-Users
- Diagnostic & Research Laboratories
- Hospitals
- Others
Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Key Players
- Alma Group
- Beckman Coulter Inc.
- Bio-Rad Laboratories Inc.
- CENTOGENE N.V.
- Euro fins Scientific
- QIAGEN
- GENOME LIFE SCIENCES
- Hoffmann-La Roche Ltd.
- Myriad Genetics Inc.
- Sema4
- Thermo Fisher Scientific Inc.
Competitive Landscape
The genomic biomarkers market is extremely competitive due to the huge number of competitors. Major players in the global genomic biomarkers market include Alma Group, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., CENTOGENE N.V., Euro fins Scientific, QIAGEN, GENOME LIFE SCIENCES, Hoffmann-La Roche Ltd, Myriad Genetics, Inc, Sema4, and Thermo Fisher Scientific Inc.
Many companies have adopted research and development as a tool to withstand the competition along with expansions, joint ventures, acquisitions, and others to increase their market share. The strategy will help to provide better quality and new features to customers.
Table Of Content
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Genomic Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Genomic Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Genomic Biomarkers Market - Supply Chain
4.5. Global Genomic Biomarkers Market Forecast
4.5.1. Genomic Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Genomic Biomarkers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Genomic Biomarkers Market Absolute $ Opportunity
5. Global Genomic Biomarkers Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Genomic Biomarkers Market Size and Volume Forecast by Applications
5.3.1. Oncology
5.3.2.
Cardiovascular Diseases
5.3.3.
Neurological Diseases
5.3.4.
Renal Disorders
5.3.5.
Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Genomic Biomarkers Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Genomic Biomarkers Market Size and Volume Forecast by End Users
6.3.1. Diagnostic & Research Laboratories
6.3.2.
Hospitals
6.3.3.
Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Genomic Biomarkers Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Genomic Biomarkers Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Genomic Biomarkers Demand Share Forecast, 2019-2026
8. North America Genomic Biomarkers Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Genomic Biomarkers Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Genomic Biomarkers Market Size and Volume Forecast by Applications
8.4.1. Oncology
8.4.2.
Cardiovascular Diseases
8.4.3.
Neurological Diseases
8.4.4.
Renal Disorders
8.4.5.
Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. North America Genomic Biomarkers Market Size and Volume Forecast by End Users
8.7.1. Diagnostic & Research Laboratories
8.7.2.
Hospitals
8.7.3.
Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Genomic Biomarkers Demand Share Forecast, 2019-2026
9. Latin America Genomic Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Genomic Biomarkers Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Genomic Biomarkers Market Size and Volume Forecast by Applications
9.4.1. Oncology
9.4.2.
Cardiovascular Diseases
9.4.3.
Neurological Diseases
9.4.4.
Renal Disorders
9.4.5.
Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Latin America Genomic Biomarkers Market Size and Volume Forecast by End Users
9.7.1. Diagnostic & Research Laboratories
9.7.2.
Hospitals
9.7.3.
Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Genomic Biomarkers Demand Share Forecast, 2019-2026
10. Europe Genomic Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Genomic Biomarkers Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Genomic Biomarkers Market Size and Volume Forecast by Applications
10.4.1. Oncology
10.4.2.
Cardiovascular Diseases
10.4.3.
Neurological Diseases
10.4.4.
Renal Disorders
10.4.5.
Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Europe Genomic Biomarkers Market Size and Volume Forecast by End Users
10.7.1. Diagnostic & Research Laboratories
10.7.2.
Hospitals
10.7.3.
Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Genomic Biomarkers Demand Share Forecast, 2019-2026
11. Asia Pacific Genomic Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Genomic Biomarkers Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Genomic Biomarkers Market Size and Volume Forecast by Applications
11.4.1. Oncology
11.4.2.
Cardiovascular Diseases
11.4.3.
Neurological Diseases
11.4.4.
Renal Disorders
11.4.5.
Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Asia Pacific Genomic Biomarkers Market Size and Volume Forecast by End Users
11.7.1. Diagnostic & Research Laboratories
11.7.2.
Hospitals
11.7.3.
Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Genomic Biomarkers Demand Share Forecast, 2019-2026
12. Middle East & Africa Genomic Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Genomic Biomarkers Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Genomic Biomarkers Market Size and Volume Forecast by Applications
12.4.1. Oncology
12.4.2.
Cardiovascular Diseases
12.4.3.
Neurological Diseases
12.4.4.
Renal Disorders
12.4.5.
Others
12.5. Basis Point Share (BPS) Analysis by Applications
12.6. Y-o-Y Growth Projections by Applications
12.7. Middle East & Africa Genomic Biomarkers Market Size and Volume Forecast by End Users
12.7.1. Diagnostic & Research Laboratories
12.7.2.
Hospitals
12.7.3.
Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Genomic Biomarkers Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Genomic Biomarkers Market: Market Share Analysis
13.2. Genomic Biomarkers Distributors and Customers
13.3. Genomic Biomarkers Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Alma Group
13.4.2.
Beckman Coulter Inc.
13.4.3.
Bio-Rad Laboratories Inc.
13.4.4.
CENTOGENE N.V.
13.4.5.
Euro fins Scientific
13.4.6.
QIAGEN
13.4.7.
GENOME LIFE SCIENCES
13.4.8.
Hoffmann-La Roche Ltd.